Researchers search for ways to predict antimalarial drug resistance and identify more effective drug combinations.

Transcript

The front-line treatment for malaria is typically a combination of drugs called artemisinin-based combination therapy. Resistance to treatment has already been reported in mild cases of malaria, but now, for the first time, it’s also being reported in severe cases of malaria. Severe malaria cases are more likely to end in a fatal outcome, so drug resistance in these scenarios poses a risk to human life. To try and stay one step ahead of resistance, researchers tested compounds and combed through publications to identify 118 compounds active against over 700 parasite clones to see how the parasites evolve under pressure, and to identify mutations in the parasite genome likely to be associated with drug resistance. They confirmed that Plasmodium falciparum – the deadliest and most prevalent species of the malaria parasite – evolves relatively easily, with mutations that affect the drug’s mechanism of action and which move through the population. The hope is that this dataset of drug resistance markers could provide an ‘early warning system’ – to predict drug resistance in the field and to identify a more effective drug combination.

Source

Artemisinin Partial Resistance in Ugandan Children With Complicated Malaria (JAMA)

Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance (Science)

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

The World Health Organization has today released its annual World Malaria Report. Here are the takeaways.

Transcript

The World Health Organization has today released its annual World Malaria Report. Here are the takeaways. Since the turn of the century, the global malaria community has averted over 2.2 billion malaria cases and 12.7 million deaths, with over a million deaths prevented in 2023 alone. Yet, despite significant progress, major gaps remain. In 2023, there were 263 million malaria cases globally, up 11 million from the year before, and nearly the same number of deaths. This means we’re off course against key WHO targets, with the case rate amongst at-risk populations three times higher than hoped, and a funding gap of over $4bn. It’s hoped that a ‘Big Push’ of political and capital commitment could accelerate efforts against the disease, help overcome drug and insecticide resistance, and improve access to new bed nets, drugs, and vaccines. But, as ever, this is dependent on funding, political will, and as this year’s report notes, a special focus on equity. There’s a need to disaggregate data to reveal the nuances of malaria transmission and understand how the disease intersects with gender equality, health equity and human rights.

Source

World malaria report 2024

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

An innovative, non-invasive diagnostic tool that could revolutionize malaria testing, with the potential to be built into wearable devices.

In this extended episode of the Johns Hopkins Malaria Minute, we ask:

• What are the limitations of current malaria diagnostic methods?
• How is a 'cytophone' - and what makes it innovative?
• Why is the detection of hemozoin significant in malaria diagnostics?
• How does interdisciplinary collaboration contribute to technological innovation?

With Sunil Parikh, Vladimir Zharov and Yap Boum

About The Podcast

The Johns Hopkins Malaria Minute is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.